Fighting Epilepsy with Nanomedicines-Is This the Right Weapon?

Bibliographic Details
Main Author: Matias, Mariana
Publication Date: 2023
Other Authors: Santos, Adriana O., Silvestre, Samuel, Alves, Gilberto
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: https://hdl.handle.net/10316/114005
https://doi.org/10.3390/pharmaceutics15020306
Summary: Epilepsy is a chronic and complex condition and is one of the most common neurological diseases, affecting about 50 million people worldwide. Pharmacological therapy has been, and is likely to remain, the main treatment approach for this disease. Although a large number of new antiseizure drugs (ASDs) has been introduced into the market in the last few years, many patients suffer from uncontrolled seizures, demanding the development of more effective therapies. Nanomedicines have emerged as a promising approach to deliver drugs to the brain, potentiating their therapeutic index. Moreover, nanomedicine has applied the knowledge of nanoscience, not only in disease treatment but also in prevention and diagnosis. In the current review, the general features and therapeutic management of epilepsy will be addressed, as well as the main barriers to overcome to obtain better antiseizure therapies. Furthermore, the role of nanomedicines as a valuable tool to selectively deliver drugs will be discussed, considering the ability of nanocarriers to deal with the less favourable physical-chemical properties of some ASDs, enhance their brain penetration, reduce the adverse effects, and circumvent the concerning drug resistance.
id RCAP_d0120b47479d0283acf89bcd8a8a01ee
oai_identifier_str oai:estudogeral.uc.pt:10316/114005
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Fighting Epilepsy with Nanomedicines-Is This the Right Weapon?antiseizure drugsepilepsylipid-based nanosystemspolymeric nanoparticlesnanomedicinesnanotechnologyEpilepsy is a chronic and complex condition and is one of the most common neurological diseases, affecting about 50 million people worldwide. Pharmacological therapy has been, and is likely to remain, the main treatment approach for this disease. Although a large number of new antiseizure drugs (ASDs) has been introduced into the market in the last few years, many patients suffer from uncontrolled seizures, demanding the development of more effective therapies. Nanomedicines have emerged as a promising approach to deliver drugs to the brain, potentiating their therapeutic index. Moreover, nanomedicine has applied the knowledge of nanoscience, not only in disease treatment but also in prevention and diagnosis. In the current review, the general features and therapeutic management of epilepsy will be addressed, as well as the main barriers to overcome to obtain better antiseizure therapies. Furthermore, the role of nanomedicines as a valuable tool to selectively deliver drugs will be discussed, considering the ability of nanocarriers to deal with the less favourable physical-chemical properties of some ASDs, enhance their brain penetration, reduce the adverse effects, and circumvent the concerning drug resistance.MDPI2023-01-17info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://hdl.handle.net/10316/114005https://hdl.handle.net/10316/114005https://doi.org/10.3390/pharmaceutics15020306eng1999-4923Matias, MarianaSantos, Adriana O.Silvestre, SamuelAlves, Gilbertoinfo:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-03-14T10:10:28Zoai:estudogeral.uc.pt:10316/114005Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T06:06:51.701158Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Fighting Epilepsy with Nanomedicines-Is This the Right Weapon?
title Fighting Epilepsy with Nanomedicines-Is This the Right Weapon?
spellingShingle Fighting Epilepsy with Nanomedicines-Is This the Right Weapon?
Matias, Mariana
antiseizure drugs
epilepsy
lipid-based nanosystems
polymeric nanoparticles
nanomedicines
nanotechnology
title_short Fighting Epilepsy with Nanomedicines-Is This the Right Weapon?
title_full Fighting Epilepsy with Nanomedicines-Is This the Right Weapon?
title_fullStr Fighting Epilepsy with Nanomedicines-Is This the Right Weapon?
title_full_unstemmed Fighting Epilepsy with Nanomedicines-Is This the Right Weapon?
title_sort Fighting Epilepsy with Nanomedicines-Is This the Right Weapon?
author Matias, Mariana
author_facet Matias, Mariana
Santos, Adriana O.
Silvestre, Samuel
Alves, Gilberto
author_role author
author2 Santos, Adriana O.
Silvestre, Samuel
Alves, Gilberto
author2_role author
author
author
dc.contributor.author.fl_str_mv Matias, Mariana
Santos, Adriana O.
Silvestre, Samuel
Alves, Gilberto
dc.subject.por.fl_str_mv antiseizure drugs
epilepsy
lipid-based nanosystems
polymeric nanoparticles
nanomedicines
nanotechnology
topic antiseizure drugs
epilepsy
lipid-based nanosystems
polymeric nanoparticles
nanomedicines
nanotechnology
description Epilepsy is a chronic and complex condition and is one of the most common neurological diseases, affecting about 50 million people worldwide. Pharmacological therapy has been, and is likely to remain, the main treatment approach for this disease. Although a large number of new antiseizure drugs (ASDs) has been introduced into the market in the last few years, many patients suffer from uncontrolled seizures, demanding the development of more effective therapies. Nanomedicines have emerged as a promising approach to deliver drugs to the brain, potentiating their therapeutic index. Moreover, nanomedicine has applied the knowledge of nanoscience, not only in disease treatment but also in prevention and diagnosis. In the current review, the general features and therapeutic management of epilepsy will be addressed, as well as the main barriers to overcome to obtain better antiseizure therapies. Furthermore, the role of nanomedicines as a valuable tool to selectively deliver drugs will be discussed, considering the ability of nanocarriers to deal with the less favourable physical-chemical properties of some ASDs, enhance their brain penetration, reduce the adverse effects, and circumvent the concerning drug resistance.
publishDate 2023
dc.date.none.fl_str_mv 2023-01-17
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10316/114005
https://hdl.handle.net/10316/114005
https://doi.org/10.3390/pharmaceutics15020306
url https://hdl.handle.net/10316/114005
https://doi.org/10.3390/pharmaceutics15020306
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1999-4923
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833602580412891136